Amicus Therapeutics Inc (FOLD) Stock Analysis

Amicus Therapeutics Inc (FOLD) is a publicly traded company in the HEALTHCARE sector. It trades at $14.49. This page summarizes the public market data, fundamentals, and frequently asked questions for FOLD, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Amicus Therapeutics Inc currently has a Neutral sentiment score of 0.08.

About Amicus Therapeutics Inc

Amicus Therapeutics, Inc. (FOLD) is a pioneering biopharmaceutical firm based in Philadelphia, Pennsylvania, committed to developing innovative therapies for rare metabolic disorders. Utilizing its proprietary enzyme replacement therapy platform, Amicus focuses on creating personalized medicine solutions that cater to previously neglected patient populations. The company boasts a promising pipeline of advanced therapeutics targeting lysosomal storage disorders, solidifying its reputation as a...

GNG Research Analysis

GNG Research scores Amicus Therapeutics Inc (FOLD) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for FOLD.

Frequently Asked Questions

Does FOLD pay dividends?

Amicus Therapeutics Inc (FOLD) does not currently pay a regular dividend.